Temozolomide for 1p19q co-deleted and partially deleted gliomas

Mairead Mcnamara; Haiyan Jiang; Mary Jane Lim Fat; Solmaz Sahebjam; Tim Rasmus Kiehl; Jason Karamchandani; Claire Coire; Caroline Chung; Barbara-Ann Millar; Normand Laperriere; Warren P Mason

Temozolomide for 1p19q co-deleted and partially deleted gliomas

Mairead Mcnamara, Haiyan Jiang, Mary Jane Lim Fat, Solmaz Sahebjam, Tim Rasmus Kiehl, Jason Karamchandani, Claire Coire, Caroline Chung, Barbara-Ann Millar, Normand Laperriere, Warren P Mason

Research output: Contribution to conference › Other

Abstract

Background Radiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA). This retrospective review investigates outcomes with upfront temozolomide (TMZ) alone in 1p19q codeleted/partially deleted AOD, AOA, oligodendroglioma (OD) or oligoastrocytoma (OA).Methods Patients (pts) with 1p19q codeleted/partially deleted AOD, AOA, OD and OA were analyzed for OS and progression free survival (PFS) using Kaplan-Meier method, and prognostic factors using Cox proportional hazard model.Results A total of 106 pts (Dec 97-Dec 13) were included. Median (med) age was 40 yrs (19-66), 58 (55%) male, performance status (PS) 0 in 80 (75%) pts. 1p19q status was codeleted in 66 (62%), incompletely codeleted in 27 (25%), 1p or 19q loss alone in 4 (4%) and 9 (8%) pts respectively. Upfront treatment was given in 72 (68%) pts; TMZ alone in 52 (49%) was well tolerated with med 12 cycles (1-24). Med time to radiotherapy in 47 pts (44%); 34.7 mo, 41.2 mo in 9 pts with codeleted/incompletely codeleted AOD who received upfront TMZ alone. Med OS was not reached for all groups (med follow up 5.1yrs) [Table]. On multivariable analysis, PS 1 vs 0 (Hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.57-4.93, p

Original language	English
Publication status	Published - 27 Sept 2014
Event	European Society of Medical Oncology - Madrid Duration: 26 Sept 2014 → 30 Sept 2014

Conference

Conference	European Society of Medical Oncology
City	Madrid
Period	26/09/14 → 30/09/14

Keywords

1p19q codeleted glioma
Temozolomide
PCV
Radiotherapy

Cite this

@conference{9b1676f5866b4c6a85f31422c168ee69,

title = "Temozolomide for 1p19q co-deleted and partially deleted gliomas",

abstract = "Background Radiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA). This retrospective review investigates outcomes with upfront temozolomide (TMZ) alone in 1p19q codeleted/partially deleted AOD, AOA, oligodendroglioma (OD) or oligoastrocytoma (OA).Methods Patients (pts) with 1p19q codeleted/partially deleted AOD, AOA, OD and OA were analyzed for OS and progression free survival (PFS) using Kaplan-Meier method, and prognostic factors using Cox proportional hazard model.Results A total of 106 pts (Dec 97-Dec 13) were included. Median (med) age was 40 yrs (19-66), 58 (55%) male, performance status (PS) 0 in 80 (75%) pts. 1p19q status was codeleted in 66 (62%), incompletely codeleted in 27 (25%), 1p or 19q loss alone in 4 (4%) and 9 (8%) pts respectively. Upfront treatment was given in 72 (68%) pts; TMZ alone in 52 (49%) was well tolerated with med 12 cycles (1-24). Med time to radiotherapy in 47 pts (44%); 34.7 mo, 41.2 mo in 9 pts with codeleted/incompletely codeleted AOD who received upfront TMZ alone. Med OS was not reached for all groups (med follow up 5.1yrs) [Table]. On multivariable analysis, PS 1 vs 0 (Hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.57-4.93, p",

keywords = "1p19q codeleted glioma, Temozolomide, PCV, Radiotherapy",

author = "Mairead Mcnamara and Haiyan Jiang and Fat, {Mary Jane Lim} and Solmaz Sahebjam and Kiehl, {Tim Rasmus} and Jason Karamchandani and Claire Coire and Caroline Chung and Barbara-Ann Millar and Normand Laperriere and Mason, {Warren P}",

year = "2014",

month = sep,

day = "27",

language = "English",

note = "European Society of Medical Oncology ; Conference date: 26-09-2014 Through 30-09-2014",

}

TY - CONF

T1 - Temozolomide for 1p19q co-deleted and partially deleted gliomas

AU - Mcnamara, Mairead

AU - Jiang, Haiyan

AU - Fat, Mary Jane Lim

AU - Sahebjam, Solmaz

AU - Kiehl, Tim Rasmus

AU - Karamchandani, Jason

AU - Coire, Claire

AU - Chung, Caroline

AU - Millar, Barbara-Ann

AU - Laperriere, Normand

AU - Mason, Warren P

PY - 2014/9/27

Y1 - 2014/9/27

N2 - Background Radiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA). This retrospective review investigates outcomes with upfront temozolomide (TMZ) alone in 1p19q codeleted/partially deleted AOD, AOA, oligodendroglioma (OD) or oligoastrocytoma (OA).Methods Patients (pts) with 1p19q codeleted/partially deleted AOD, AOA, OD and OA were analyzed for OS and progression free survival (PFS) using Kaplan-Meier method, and prognostic factors using Cox proportional hazard model.Results A total of 106 pts (Dec 97-Dec 13) were included. Median (med) age was 40 yrs (19-66), 58 (55%) male, performance status (PS) 0 in 80 (75%) pts. 1p19q status was codeleted in 66 (62%), incompletely codeleted in 27 (25%), 1p or 19q loss alone in 4 (4%) and 9 (8%) pts respectively. Upfront treatment was given in 72 (68%) pts; TMZ alone in 52 (49%) was well tolerated with med 12 cycles (1-24). Med time to radiotherapy in 47 pts (44%); 34.7 mo, 41.2 mo in 9 pts with codeleted/incompletely codeleted AOD who received upfront TMZ alone. Med OS was not reached for all groups (med follow up 5.1yrs) [Table]. On multivariable analysis, PS 1 vs 0 (Hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.57-4.93, p

AB - Background Radiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA). This retrospective review investigates outcomes with upfront temozolomide (TMZ) alone in 1p19q codeleted/partially deleted AOD, AOA, oligodendroglioma (OD) or oligoastrocytoma (OA).Methods Patients (pts) with 1p19q codeleted/partially deleted AOD, AOA, OD and OA were analyzed for OS and progression free survival (PFS) using Kaplan-Meier method, and prognostic factors using Cox proportional hazard model.Results A total of 106 pts (Dec 97-Dec 13) were included. Median (med) age was 40 yrs (19-66), 58 (55%) male, performance status (PS) 0 in 80 (75%) pts. 1p19q status was codeleted in 66 (62%), incompletely codeleted in 27 (25%), 1p or 19q loss alone in 4 (4%) and 9 (8%) pts respectively. Upfront treatment was given in 72 (68%) pts; TMZ alone in 52 (49%) was well tolerated with med 12 cycles (1-24). Med time to radiotherapy in 47 pts (44%); 34.7 mo, 41.2 mo in 9 pts with codeleted/incompletely codeleted AOD who received upfront TMZ alone. Med OS was not reached for all groups (med follow up 5.1yrs) [Table]. On multivariable analysis, PS 1 vs 0 (Hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.57-4.93, p

KW - 1p19q codeleted glioma

KW - Temozolomide

KW - PCV

KW - Radiotherapy

M3 - Other

T2 - European Society of Medical Oncology

Y2 - 26 September 2014 through 30 September 2014

ER -

Temozolomide for 1p19q co-deleted and partially deleted gliomas

Abstract

Conference

Keywords

Fingerprint

Cite this